THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS
Aim: To evaluate retrospectively the efficacy and safety of entecavir in treatment-naïve patients with hepatitis B viral infection.Materials and methods: Based on patient medical documentation, we analyzed the results of clinical, virologic and instrumental assessment of 36 patients with chronic hep...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
MONIKI
2016-02-01
|
| Series: | Alʹmanah Kliničeskoj Mediciny |
| Subjects: | |
| Online Access: | https://www.almclinmed.ru/jour/article/view/109 |
| _version_ | 1818906957536296960 |
|---|---|
| author | L. I. Mel'nikova L. Yu. Il'chenko |
| author_facet | L. I. Mel'nikova L. Yu. Il'chenko |
| author_sort | L. I. Mel'nikova |
| collection | DOAJ |
| description | Aim: To evaluate retrospectively the efficacy and safety of entecavir in treatment-naïve patients with hepatitis B viral infection.Materials and methods: Based on patient medical documentation, we analyzed the results of clinical, virologic and instrumental assessment of 36 patients with chronic hepatitis B, 6 of whom were HBeAg-positive, and 1 had a highly active progression of acute hepatitis B. Duration of entecavir therapy (at a dose of 0,5–1 mg daily) was 48 weeks.Results: In most patients with chronic hepatitis B, treatment with entecavir, regardless of the HBeAg status, promoted a virologic response (94.4%) and HBeAg serum conversion with anti-HBe formation (83.3%), which was associated with a clinical improvement, normalization of liver enzyme activity, reduction of liver fibrosis by 1 point (assessed by fibroelastometry). There were no changes in serum HBsAg during the antiviral therapy. A clinical case of successful entecavir therapy of hepatitis B viral infection is presented. Conclusion: Entecavir is a highly effective and reliable agent that can suppress viral replication in various forms of acute and chronic hepatitis B viral infection. A relatively rapid recurrence of viral replication after withdrawal of the drug justifies further research to optimize treatment of chronic hepatitis B. |
| first_indexed | 2024-12-19T21:47:29Z |
| format | Article |
| id | doaj.art-e578fb81fe3c4ce0a2c2343641a2f616 |
| institution | Directory Open Access Journal |
| issn | 2072-0505 2587-9294 |
| language | Russian |
| last_indexed | 2024-12-19T21:47:29Z |
| publishDate | 2016-02-01 |
| publisher | MONIKI |
| record_format | Article |
| series | Alʹmanah Kliničeskoj Mediciny |
| spelling | doaj.art-e578fb81fe3c4ce0a2c2343641a2f6162022-12-21T20:04:30ZrusMONIKIAlʹmanah Kliničeskoj Mediciny2072-05052587-92942016-02-010409010010.18786/2072-0505-2015-40-90-100109THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASISL. I. Mel'nikova0L. Yu. Il'chenko1The Central Medical Unit No. 165 of the Federal Biomedical Agency of Russia, MoscowChumakov Institute of Poliomyelitis and Viral Encephalitides, MoscowAim: To evaluate retrospectively the efficacy and safety of entecavir in treatment-naïve patients with hepatitis B viral infection.Materials and methods: Based on patient medical documentation, we analyzed the results of clinical, virologic and instrumental assessment of 36 patients with chronic hepatitis B, 6 of whom were HBeAg-positive, and 1 had a highly active progression of acute hepatitis B. Duration of entecavir therapy (at a dose of 0,5–1 mg daily) was 48 weeks.Results: In most patients with chronic hepatitis B, treatment with entecavir, regardless of the HBeAg status, promoted a virologic response (94.4%) and HBeAg serum conversion with anti-HBe formation (83.3%), which was associated with a clinical improvement, normalization of liver enzyme activity, reduction of liver fibrosis by 1 point (assessed by fibroelastometry). There were no changes in serum HBsAg during the antiviral therapy. A clinical case of successful entecavir therapy of hepatitis B viral infection is presented. Conclusion: Entecavir is a highly effective and reliable agent that can suppress viral replication in various forms of acute and chronic hepatitis B viral infection. A relatively rapid recurrence of viral replication after withdrawal of the drug justifies further research to optimize treatment of chronic hepatitis B.https://www.almclinmed.ru/jour/article/view/109acute hepatitis bchronic hepatitis btreatmententecavir |
| spellingShingle | L. I. Mel'nikova L. Yu. Il'chenko THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS Alʹmanah Kliničeskoj Mediciny acute hepatitis b chronic hepatitis b treatment entecavir |
| title | THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS |
| title_full | THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS |
| title_fullStr | THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS |
| title_full_unstemmed | THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS |
| title_short | THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS |
| title_sort | experience of entecavir use in patients with hepatitis b viral infection on an outpatient basis |
| topic | acute hepatitis b chronic hepatitis b treatment entecavir |
| url | https://www.almclinmed.ru/jour/article/view/109 |
| work_keys_str_mv | AT limelnikova theexperienceofentecaviruseinpatientswithhepatitisbviralinfectiononanoutpatientbasis AT lyuilchenko theexperienceofentecaviruseinpatientswithhepatitisbviralinfectiononanoutpatientbasis AT limelnikova experienceofentecaviruseinpatientswithhepatitisbviralinfectiononanoutpatientbasis AT lyuilchenko experienceofentecaviruseinpatientswithhepatitisbviralinfectiononanoutpatientbasis |